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otlowod for 50 of 51 pt~ to remain in sinus rhythm during their individual 
follow-up period, 
Conclusion: Motfix lAD Ilns boon operating as intended in lhe~o patients 
The clinical trial resells with the Molrlx lAD syslem have boon promls=ng in 
tllnl the majority of tile pts have experienced evice terminated spontnneous 
opi~Qdo~ and have fl~oroby boon eLlle to remnln tn sinus rhythm, 
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~ Echocardlographla Predl©tora for Maintenance of 
£;Inua Rhythm Following Suc~aeatui Internal Atrial 
DMIbrillation of Chronla Atrial FlbrlllMIon 
H, Omran, W, Juno, B, Rang, ~, Illlon, R, Sgl~impl, H B~ollor, C, Wotport, 
I],, L(ldorlt~, Dop~Irtte~nt of Cnrdlelog~ Llni~r~lfj, of t]nnn, Bonn, Germnny 
B~ckground: Chront¢~ slrlnl flbrlltafton (AF) v, hi~;h i~ resistanl to oxtorn~'d o10c. 
Irlosl DC-~hock or pharmacological onrdioversion may be stt~cocMully car. 
dlovorted by tnfornnt atrial defibrillation (tAD), However, to avoid unne~soo. 
~aq/ lAD In patients wllh chronic AF il ts important In predict ltltl p~ttents 
whicl~ will revert to AF, The aim ot tile study was to delermlno, wllother 
ochoc~rdtogrophlc p~ramolor~ may predict Ilia recurmnt:e ot AF, 
Method.~; 31 paltanls wilh chronlc~ AF (~3 m, 8 f, ago 50 t g yearn, durattnn 
~f the I~ l  episode 14£1 t 130 dftys) undol~vonl StlCCesslol (AI~. fi months 
following lAD the ro~uHonco f AF was n~ftosaed, Loll atrial dt,"~metor (LAD), 
loll vontricular ejection hnction (EFt, mnxlmam loll ~trlnl appaodngo otoa 
(LAAflroa) nnd left ~trtnl ~ppond~go luncllon as assossQd by peak emptying 
votOClllOs el fhn t AA (LAAv) were nn~lyzed to determine the recurrence el 
AF, 
Re.'~tdts: 3 p~ttonts wore Iosl 1o Iollow up ~ months attar lAD 50% el 
p~t(~nts h~d rocurmnoo of AF 
EF (%1 LAD (errs) I,AA ='t~Ol~ (cm~) LAAv fro(st 
SR(,~ 14) 50 ~ 1,t 42 * (It'~ 5,4 ~ 1 7 a50 ~ 02 
AF(n~ 14~ 5t = 13 45 = e? ti;.~ 1 21 026 ~ et  
The odd~ ratio for recurrence el AF Is 613 (95% conlidooco intowal: 
t 63-,-2~,03) wlll~ a LAAv • 0.35 m/s, 
Conclusions ElOcllon fraction and loft final size are not predictive of 
recurrence Of ntrlnl flbnnntton following succosslul internal alrial defibrillation 
o1 chronic atrial fibrillalion, However, depressed loll atnnt appendage luncbon 
tory be used as n marker to identify those pnllonts which wdl revert to atnal 
fibrillation after internal atrial defibr~nahon of chronic areal hbrdlahon 
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~ ]  Electrlea, or Pharmacolonlc Cerdloverslon of Atria, 
Flbr I atlon: Does the Ven'trlole Really Care? 
JIk~ DoCara, VM Abascal, R,H Folk Boston Umv~rslty Sch~'~l of 
Mechcine. ~oston, MA, USA 
Atfial fibnll~lion (AFt may adversely affect post-cardiovorsion {CV) atnal 
function and cause reversible vontrtcular dy lunction. Controversy exists 
whether peal CV atrial stunning is less with pham'lncoleg~c (pharm) CV than 
oloctncal CV, but no study has addressed the relative effects of pharm and 
olectfical CV on pesI-CV venlncular hemodynamics. We thus performed 
quantitatwe cho-Doppler =n 18 pts who I~ad pl~armacologtc conversion el 
AF after oral dofotitido and compared them to 19 pts rcqt.nng eloclfical CV 
receiving the same drag, Baseline parameters wore the same in both groups. 
For the 37 pt, CV was associated wilh a statistically signif*cant decrease in 
HR and increase in stroke volume (SV) without significant change in cardiac 
output (CO) or eieclion fraction (EFt, Companson of percentage change in 
homodynamic parameters in pharm and electncally converted pf showed no 
difference between Iho groups. 
% Change in Homodvnarn=cs Alter qestorah~,n ofNSR" 
HR SV CO EF 
Ph~m~ CV ~74~o +1 p,o,, 3~'- ÷31"o 
Electrical C ~t t 67% + 175% 0% +74% 
• D = tl~ tot ~ comparl$oP, s between pharrl~ L~nd electric CV 
Conclu~ ,as: Although cardioversion of AF to NSR is asso,':ialed with 
s=gni[;cant -,,angos in hemodynam;cs and stroke volume, the mode of CV 
{electrical ~t pharmacologic) has no effect upon these changes. Thus any 
adverse effects of CV on the atrium are nol transmitted to the ventricle 
11:45 
1845-61 Atrial Fibrillation: Favorable Effects of Flecelnlda In 
"rranavenoua Low Energy Internal Atrial 
Carclloverslon 
G. Bonani, M, Biffi, A, Capucc*, G. Bronzetti, G=M Ayem, A, Bran~i, 
B, Mngnttni, Institute of Cardiology, University of Elofogntl, Italy: In Control 
Inc,, Redmond WA, USA 
The effects of intravenous (i,v,) flocninldo (FL) worn tested in 24 pntionls (pts) 
submitted to transvonous low (~norgy c~rdiovomion (CV): 19 had chronic 
atrial fibrillation (OAF), B pt~, had pamwysm,'ll atrial hbnllaflon (PAF), R wav~) 
~'tn=~,rontsod 3/3 ms biph~sio sllocks worn delivered t~Ohvoon fight fltna! 
sad ooronsPf sinus olootmdos, by 40V stops, beginning at 20-.50 V up to 
convomion or to 400-~50V, Alter successful CV, ~ust~lnod AF was indocod, 
Ilion i,v, FL (2 mg/kg) woe, administered and CV was tested again, Shocks 
for CV worn repeated altar FL ovco in p!s, not converted at baseline. 
Results: In CAF CV was effective in 13/t9 (6Q%) pts. at baseline and m 
10119 (84%) pt~,, allot FL, In 3 ply. oonvorsion was obtained only alter FL In 
PAF CV was effective in all lhe pts, 0ifh0r al baseline and alter FL Alter FL 
sign!hoof! reductions io oltecIw0 shocks !oadlfig edge voltages (CAF = from 
3~t t 38 lo 284 t 54 V, p - 0.005; PAF = 184 r 2;' to 130 r 34 V p .. 0.005) 
and ~rrespondlng energies (CAF = from 4,4~ r 1 37 to 3 50 t t 5t J, P .  
0.005; PAF = from 1tab t 02910084 t 0.2£i J, p ~ 001) were obsente(t 
logethor with a stgnllicanl roduc!ton in subjective score for shock induco¢l 
discomfort (from 4.29 t O81 to 3.71 t O 83, p ~ 0.005) in pts. not requmng 
sod~tlon (75"0) No ventncular proarrhylhmlc effects were observed 
In eonclusloa i.v FL has favorable effects m transvenous CV because 
It Iowols dohbnllatloo energy requirements and consoquenOy lowers shock 
Induced d~soomfort Moreover FL may moroaso the proc, odure success r~te 
m OAF, 
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~ 846-2J Pmthrombotlc and Reduced Flbrinolytlc State in 
Association With Homocystelnemia: The 
Framlngham Offspring Study 
GH. Toiler, H. Silborshatz, R.B. D'Agostino, P WF Wilson. P Suthedand, 
I Lipmska, MA. Milliemes, PF. Jacques, A. Bostom, J. Selhub Beth Israe~ 
Deaconess Afedtca/Center. Frammgham Heart Stu~'. Boston. MA. USA 
The mechanism by which elevated homocystome levels increase the nsk of 
cardiovascular disease (CVD) has not been well explained Since thrombosis 
plays a meier role m the onset of CMD. we deten~med whether homo~,s- 
fame levels were associated with thrombotic and fibnnolyttc measures. We 
studied 2717 subjecls wilhoul known CVD trom cycle 5 el the Frammgham 
Offspnng Study (1234 men. 1483 women). Fasting homocysteine levels were 
measured as were plasminogen activator inhibitor antigen (PAI-t } and tissue 
ptasminogen activator antigen (TEA), yon Willebrand Factor. Faclor VII. and 
llbnnogen, The age and gender adjusted associations were determined using 
regression analysis. Results were similar by gender, although the trends were 
stronger among women The signdicanl assoc*ations remained when further 
adiustmg tor body mass index, smoking, diabetes, total and HDL-cholesterol. 
and triglycerides 
Mean values by Qglntllo ot HomocystOmo Level 
UnLt 1 st 2nd 3rd 4th 5 Ih trend In) 
'~AI- 1 (ngq'nl) 20 B 21 9 22 1 23 5 22 9 0 003 
TPA (ng'ml) 884 858 902 936 941 0001 
vWF (%) 124 124 127 129 t29 0011 
FactowVII (%) 98 100 100 100 t00 0 008 
Fibnnogen (rag dl) 299 306 310 309 300 0 943 
Conclusion: Higher homocysteine levels were associated with a pro- 
thrombotic and reduced fibrinolytic stale. This may represent a mechanism 
by which homoeysleine levels modify cardiovascular risk, 
